Axsome Therapeutics Secures FDA Approval for AUVELITY in Alzheimer’s Agitation
NEW YORK, April 30, 2026 LAxsome Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Neuropsychiatry
Advertisement
Johnson & Johnson Strengthens CNS Portfolio with CAPLYTA FDA Nod
TITUSVILLE, NEW JERSEY, April 27, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for...
Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
Axsome Acquires Balipodect to Expand CNS Drug Pipeline
NEW YORK, USA — April 1, 2026 Axsome Therapeutics, Inc. has announced the acquisition of exclusive global rights to...
LB Pharma LB-102 Shows Phase 2 Cognitive Benefits in Schizophrenia
New York, USA | March 27, 2026 LB Pharmaceuticals announced new findings from its Phase 2 NOVA-1 clinical trial,...
Advertisements
PureTech, Seaport Advance GlyphAllo in Depression Therapy
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
Gilgamesh Pharma Raises $60M for Neuro Therapies
NEW YORK, USA | March 24, 2026 Gilgamesh Pharma, a clinical-stage neuroscience company focused on next-generation neuropsychiatric therapeutics, has...
Meta-Analysis Reveals Drivers of Placebo Response in GAD
BOSTON, Feb. 20, 2026 — Seaport Therapeutics announced new findings from a comprehensive meta-analysis examining how clinical trial design...
Alto Completes Phase 2 Enrollment for CIAS Drug
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
Advertisement
